Bharat Biotech, founded by Krishna Ella and his wife Suchitra, has been at the forefront of making vaccines for a while. Yet it took a global pandemic for the spotlight to shine on the company.
In a big move, India has opened up Covid-19 vaccinations for all adults. However, the country is beset by severe vaccine shortage and other challenges. Will increasing the demand base work?
As India starts the second phase of its Covid-19 vaccine deployment, the question on the viability of its supply chain network, and its cold storage capability, has become more pertinent than ever.
The massive campaign to deploy the Covid-19 vaccine rests on infrastructure, both physical and digital. Using past campaigns, India put together a multi-pronged strategy for a smooth roll-out.
For BBIL’s founder Krishna Ella, the roll-out of a made-in-India vaccine, Covaxin, is peppered with challenges. Two recent deals with Brazilian and American firms have now buoyed him.
The DCGI has given the nod for two vaccines and phase 1 of the vaccination process is expected to begin soon. Zydus Cadila’s vaccine candidate has also been cleared for phase 3 trials.
Three firms have applied for emergency use authorisation in India as of now. AIIMS’ Amit Dinda, who is a part of the Global Coalition for Regulatory Science Research, explains the regulatory nuances.
